The changes include the renaming of Janssen, the company’s pharmaceutical segment, as Johnson & Johnson Innovative Medicine, while the brand will continue to incorporate the medical technology sector ...
10d
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback